Enzymotec Ltd (ENZY) Reaches $9.30 52-Week High; Quantbot Technologies LP Has Lifted Prologis (PLD) Position By $1.12 Million

August 1, 2017 - By Nellie Frank

The stock of Enzymotec Ltd (NASDAQ:ENZY) hit a new 52-week high and has $9.58 target or 3.00% above today’s $9.30 share price. The 8 months bullish chart indicates low risk for the $212.53 million company. The 1-year high was reported on Aug, 1 by Barchart.com. If the $9.58 price target is reached, the company will be worth $6.38M more. About 601,368 shares traded or 1547.58% up from the average. Enzymotec Ltd (NASDAQ:ENZY) has risen 10.01% since August 1, 2016 and is uptrending. It has underperformed by 6.69% the S&P500.

Quantbot Technologies Lp increased Prologis Inc (PLD) stake by 75.01% reported in 2016Q4 SEC filing. Quantbot Technologies Lp acquired 21,558 shares as Prologis Inc (PLD)’s stock rose 10.06%. The Quantbot Technologies Lp holds 50,298 shares with $2.66M value, up from 28,740 last quarter. Prologis Inc now has $32.65 billion valuation. The stock rose 0.94% or $0.57 reaching $61.38 per share. About 1.18M shares traded. Prologis Inc (NYSE:PLD) has risen 18.74% since August 1, 2016 and is uptrending. It has outperformed by 2.04% the S&P500.

Among 21 analysts covering Prologis (NYSE:PLD), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Prologis had 42 analyst reports since July 22, 2015 according to SRatingsIntel. Jefferies maintained Prologis Inc (NYSE:PLD) rating on Monday, July 17. Jefferies has “Hold” rating and $5900 target. The stock of Prologis Inc (NYSE:PLD) earned “Neutral” rating by Suntrust Robinson on Thursday, June 30. The stock of Prologis Inc (NYSE:PLD) has “Outperform” rating given on Wednesday, January 27 by Oppenheimer. The stock of Prologis Inc (NYSE:PLD) earned “Outperform” rating by Robert W. Baird on Wednesday, July 22. The firm has “Neutral” rating by Bank of America given on Friday, June 24. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, July 18. Bank of America upgraded the stock to “Neutral – Buy” rating in Friday, June 23 report. BB&T Capital initiated Prologis Inc (NYSE:PLD) on Thursday, November 12 with “Hold” rating. The firm earned “Hold” rating on Friday, January 22 by Jefferies. The firm has “Market Perform” rating given on Monday, November 30 by Wells Fargo.

Investors sentiment increased to 1.15 in Q4 2016. Its up 0.23, from 0.92 in 2016Q3. It improved, as 38 investors sold PLD shares while 158 reduced holdings. 53 funds opened positions while 172 raised stakes. 509.26 million shares or 1.75% less from 518.36 million shares in 2016Q3 were reported. Hgk Asset Management holds 4,353 shares or 0.03% of its portfolio. Blackrock Inv Mgmt Limited Com accumulated 1.20M shares or 0.07% of the stock. American Insurance Communications Tx reported 144,845 shares stake. Moreover, Utah Retirement Sys has 0.15% invested in Prologis Inc (NYSE:PLD) for 111,558 shares. Glenmede Com Na has 0% invested in Prologis Inc (NYSE:PLD) for 670 shares. 655,100 are owned by Prudential Public Ltd Liability. Virtu Fin Ltd invested 0.05% of its portfolio in Prologis Inc (NYSE:PLD). Ontario Teachers Pension Plan Board holds 0.07% in Prologis Inc (NYSE:PLD) or 129,071 shares. Rothschild Asset Mngmt holds 0.62% of its portfolio in Prologis Inc (NYSE:PLD) for 926,685 shares. Holt Cap Advisors Ltd Co Dba Holt Cap Partners LP holds 7,876 shares or 0.15% of its portfolio. State Teachers Retirement Sys holds 0.12% or 882,707 shares. Allianz Asset Ag invested in 0.03% or 582,350 shares. Fifth Third Retail Bank reported 0.1% of its portfolio in Prologis Inc (NYSE:PLD). 5.41 million were reported by Aew Mngmt Lp. First Advsr Limited Partnership holds 444,905 shares or 0.07% of its portfolio.

Quantbot Technologies Lp decreased Splunk Inc (NASDAQ:SPLK) stake by 9,330 shares to 7,221 valued at $369,000 in 2016Q4. It also reduced Texas Instruments Inc (NASDAQ:TXN) stake by 33,628 shares and now owns 12,330 shares. Msci Inc (NYSE:MSCI) was reduced too.

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The company has market cap of $212.53 million. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. It currently has negative earnings. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment.

Among 3 analysts covering Enzymotec (NASDAQ:ENZY), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Enzymotec has $11 highest and $800 lowest target. $9’s average target is -3.23% below currents $9.3 stock price. Enzymotec had 6 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, June 15 by Jefferies. The rating was maintained by Jefferies with “Hold” on Wednesday, July 19. The firm has “Outperform” rating by Wells Fargo given on Thursday, August 13.